Intuitive Surgical posts 22% revenue growth in Q3 2026, maintains Buy rating with 23% upside potential.

Intuitive Surgical reported strong Q3 2026 results with 22% revenue growth and 84% recurring revenue, supported by robust system placements. Despite competitive and geographic pressures, the updated price target of $553 reflects a balanced valuation and a 23% potential upside. Challenges like a 3%-5% decline in instrument revenue per procedure and price cuts in China are offset by growth in benign procedure adoption and installed base leverage. The outlook depends on U.S. procedure utilization, international surgery growth, FDA approvals, and 2027 pricing strategies.

Intuitive Surgical (ISRG) trades at USD 442.00 on Pluang as of Nov 13, 2026 02:51 WIB, down 1.68% for the day. This price is closer to its 52-week low of USD 332.02 than the 52-week high of USD 592.85, highlighting a significant range in its valuation over the past year. Despite the article's mention of a $553 price target, the current market price reflects a discount compared to that target level.